BioSight - Innovative Cancer Therapeutics

Biosight is dedicated to providing hope and cure to cancer patients around the world

We seek to develop advanced therapeutics to enable safer and more effective treatment for life-threatening diseases, to improve the outcome and quality of life for patients with cancer and related diseases

Innovative Therapeutics

for Oncology & Hematological Disorders

>>Advaxis and Biosight Announce Entry into Definitive Merger Agreement

>>Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

>>Biosight Appoints Dr. Darrel Cohen as Chief Medical Officer

>>Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

>>Biosight Receives Orphan Medicinal Product Designation from EMA for Aspacytarabine (BST-236) for AML Treatment
>>Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs